Rayonier Advanced Materials (RYAM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
30 Mar, 2026Executive summary
2025 financial performance was below expectations, with a $423 million loss from continuing operations and a 40% decline in adjusted EBITDA to $133 million, prompting a renewed focus on restoring profitability and cash flow in 2026.
The Board intensified oversight of operations, cost discipline, and capital allocation, and implemented a new annual incentive program for 2026 tied exclusively to EBITDA and free cash flow.
Leadership transition occurred with Scott M. Sutton appointed as President and CEO in January 2026, emphasizing operational reliability and disciplined capital spending.
Strategic priorities include restoring free cash flow, strengthening competitive positioning in Cellulose Specialties, improving operational reliability, and deleveraging.
Voting matters and shareholder proposals
Stockholders are asked to elect three Class III directors for terms expiring in 2029.
Proposals include declassifying the Board, eliminating supermajority voting provisions, advisory approval of executive compensation, approval of a French Sub-Plan under the 2023 Incentive Stock Plan, and ratification of Grant Thornton LLP as independent auditor for 2026.
The Board recommends voting FOR all proposals.
Board of directors and corporate governance
The Board is composed of nine directors, 89% of whom are independent, with a mix of skills and diversity; 56% refreshment since 2022.
Annual management succession planning and board evaluation processes are in place.
Proposals to declassify the Board and eliminate supermajority voting are reintroduced to strengthen accountability.
The Board is led by an independent Chair, with a majority voting standard for director elections.
Latest events from Rayonier Advanced Materials
- Key votes include board declassification, supermajority removal, and executive pay approval.RYAM
Proxy filing30 Mar 2026 - Board refresh, CEO change, and governance reforms highlight a focus on accountability and performance.RYAM
Proxy filing20 Mar 2026 - 2026 targets positive cash flow, EBITDA growth, and new product launches amid disciplined execution.RYAM
Gabelli Funds Annual Specialty Chemicals Symposium20 Mar 2026 - 2025 results showed lower revenue and EBITDA, with 2026 targeting free cash flow recovery.RYAM
Q4 20254 Mar 2026 - Aiming to double EBITDA by 2027, leveraging price, cost, and biomaterials growth.RYAM
17th Annual Southwest IDEAS Conference3 Feb 2026 - Transformation to specialty cellulose, innovation, and sustainability drive growth and profitability.RYAM
Fireside Chat3 Feb 2026 - Shifting to specialty cellulose and biomaterials, with debt reduction and margin expansion in focus.RYAM
Small-Cap Growth Virtual Investor Conference3 Feb 2026 - Q2 net sales and earnings surged, with 2024 guidance raised and cash flow outlook improved.RYAM
Q2 20242 Feb 2026 - Shifting to specialty cellulose and biomaterials, with asset sales and debt reduction underway.RYAM
Stifel 2024 Cross Sector Insight Conference1 Feb 2026